Clinical trial
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell…
NCT00438802 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00438802 |
|---|---|
| Title | Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma |
| Official title | A Phase I Study of Alefacept (AmeviveTM) in the Treatment of Cutaneous T-cell Lymphoma and Peripheral T-cell NHL |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Alefacept |
| Enrollment | 23 |
| Start date | Mar 1, 2006 |
| Primary completion | Aug 24, 2010 |
| Completion | Jul 25, 2019 |
| First posted | Feb 22, 2007 |
| Last update posted | Aug 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: